Loading...
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The introduction of immune checkpoint inhibitors targeting prog...
Na minha lista:
| Udgivet i: | Lung Cancer (Auckl) |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6556538/ https://ncbi.nlm.nih.gov/pubmed/31239797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S176391 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|